Moderna
COVID-19 vaccines: How soon will life become normal?

Dr. Satyajit Rath talks about the progress of different vaccination campaigns and how the vaccines are faring against the different COVID variants.

COVID-19 vaccines: Differences, costs, and challenges

The COVID-19 pandemic saw the fastest development of a vaccine ever, with a number of research collaborations making this feat possible. But many challenges also remain

Vaccine rollout battle: First past the post may win major market share

India’s mass vaccination plans may fail if it does not hold open discussions on its plans with health professionals and the people

COVID-19 vaccine: Rich countries might gain, poor ones might suffer

As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard

Russia, UK, COVID vaccines UK and Russia announce start of COVID-19 vaccinations from next week

Both Russia’s Sputnik V and the UK’s Pfizer-BioNTech-produced vaccines are reported to be more than 95% effective in their final trials

Even with vaccines, it is a long and rocky road to immunity

Even if the major economies can solve their own problems of procuring the vaccines by jumping the queue with money or captive production capacities, what about the rest of the world?

oxfam COVID vaccine supply report Rich countries corner nearly 51% supply of five major COVID-19 vaccine candidates: Oxfam

According to a recent study by Oxfam International, wealthy nations, which account for nearly 13% of the global population, have cornered a lion’s share of supply deals for vaccine candidates in phase-3 of the clinical trials

COVID 19: For how long do antibodies stay?

Dr. Satyajit Rath talks about the immunity developed in recovered COVID-19 patients and also the immunity that the potential vaccines can induce.

Break Gilead’s patent since US has bought all stock of Remdesivir

Trump is trying to improve his waning electoral chances by reserving all of Gilead’s stock of Remdesivir to cover up his disastrous handling of the Covid-19 epidemic so far

    × To Subscribe